Target intelligence / Profile preview

RNA, variant U1 small nuclear 1 (RNVU1-1)

Target
RNVU1-1
Molecular classification
Small nuclear RNA (snRNA), Noncoding RNA, Spliceosomal RNA, Other
01

Overview

**RNA, variant U1 small nuclear 1** (RNVU1-1), also known as vU1.1 or by several similar aliases, is a member of the U1 small nuclear RNA gene family, composed of functional variants and pseudogenes. U1 snRNAs are essential components of the spliceosome complex responsible for recognizing 5' splice sites in pre-mRNA and facilitating splicing. Variant U1 snRNAs (vU1s) are transcribed, processed and can be assembled into snRNPs, but often differ in sequence from the canonical U1 snRNA. Most vU1s, including RNVU1-1, are expressed at much lower levels than canonical U1 snRNA and may have altered or limited capacity to facilitate normal splicing, with some variants having specific or minimal activity[1]. vU1s may also regulate alternative splicing and polyadenylation, protect nascent transcripts from premature cleavage, and modulate gene expression, particularly during developmental stages or in pluripotent stem cells[2]. Imbalances in the expression of U1/vU1 ratios have been linked to neurological diseases, including spinal muscular atrophy. RNVU1-1 is not a receptor, enzyme, transporter, or traditional therapeutic target; it is a noncoding RNA acting in RNA processing and gene expression regulation[1][2].

Other names
vU1.1U1P14U1.4vU1.10RNU1-53RNU1-10PRNU1P10RNVU1-10RNA, variant U1 small nuclear 10
02

Biological functions

Pre-mRNA splicingRegulation of alternative splicingRegulation of RNA 3' end processing (polyadenylation)Regulation of gene expressionOther
03

Disease associations

Neurodegenerative disease (imbalance in vU1/U1 ratio implicated in motor neuron diseases such as spinal muscular atrophy)Potential involvement in other diseases through disruption of alternative splicing or RNA processingOther
04

Biomarkers

Altered vU1/U1 ratio as a potential biomarker in neurodegenerative conditions such as spinal muscular atrophy[2]

Beyond the preview

Go deeper on RNA, variant U1 small nuclear 1 (RNVU1-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, variant U1 small nuclear 1 (RNVU1-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call